Novo Nordisk A/S (NYSE:NVO) Trading Up 3.1% – What’s Next?

Novo Nordisk A/S (NYSE:NVO) was up 3.1% during trading on Monday . The company traded as high as $39.88 and last traded at $39.7730. Approximately 23,690,162 shares traded hands during mid-day trading, a decline of 11% from the average daily volume of 26,533,146 shares. The stock had previously closed at $38.58.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo ended its lawsuit and will distribute Wegovy and Ozempic via Hims & Hers’ telehealth platform, opening a digital channel to millions of users and removing legal uncertainty that had been a short-term overhang. Reuters: Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
• Positive Sentiment: CEO comments and media coverage framed the agreement as a truce that preserves pricing parity on telehealth platforms and removes the risk of adverse court rulings—a de-risking event for revenue and reputation. CNBC: Hims & Hers shares surge after Novo ends legal feud
• Positive Sentiment: Novo launched an ongoing share-repurchase programme (part of up to DKK 15bn over 12 months), which supports the share base and signals management confidence in cash generation. GlobeNewswire: Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Analyst consensus remains cautious (consensus “Hold”), and brokers are updating FY2026 estimates—these are watchpoints but not immediate catalysts. AmericanBankingNews: Novo Nordisk Given Consensus “Hold”
• Negative Sentiment: Market concerns persist: Zacks highlights that NVO lost roughly $50B in market cap amid stronger clinical results from competitors (Lilly) and potential GLP‑1 price pressure—factors that could weigh on margins and valuation. Zacks: NVO Stock Sheds Nearly $50B in Market Cap
• Negative Sentiment: Some institutional selling was reported (Cresset reduced its NVO position), a reminder that positioning and flows can amplify short-term moves. DefenseWorld: Novo Nordisk Shares Sold by Cresset

Analyst Ratings Changes

NVO has been the topic of several recent analyst reports. The Goldman Sachs Group restated a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Kepler Capital Markets lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Citigroup assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 27th. They issued a “neutral” rating for the company. Finally, TD Cowen reiterated a “buy” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 3rd. Five investment analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $53.93.

Novo Nordisk A/S Trading Up 3.1%

The company’s 50 day simple moving average is $51.41 and its 200 day simple moving average is $52.35. The firm has a market cap of $177.59 billion, a price-to-earnings ratio of 11.46 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 52.74%.

Institutional Trading of Novo Nordisk A/S

Large investors have recently made changes to their positions in the company. Martin Capital Partners LLC increased its stake in Novo Nordisk A/S by 53.8% in the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after purchasing an additional 41,129 shares in the last quarter. Smith Chas P & Associates PA Cpas boosted its position in Novo Nordisk A/S by 105.3% during the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock worth $22,497,000 after purchasing an additional 207,959 shares in the last quarter. Clifford Swan Investment Counsel LLC grew its holdings in Novo Nordisk A/S by 13.7% in the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock valued at $17,267,000 after purchasing an additional 37,453 shares during the last quarter. Markel Group Inc. increased its position in shares of Novo Nordisk A/S by 4.9% in the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after buying an additional 110,061 shares in the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter worth $1,294,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.